23:21 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis B virus (HBV) Patient sample and mouse studies suggest agonizing OX40 could help treat HBV infection in patient subsets with poor viral clearance, including pediatric patients with acute infection and adults with chronic...
10:21 , Aug 24, 2017 |  BC Innovations  |  Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

AgonOx, Daiichi Sankyo deal

The companies partnered for the preclinical development of an undisclosed AgonOx immuno-oncology target. After a preclinical assessment, Daiichi may exercise an exclusive option for worldwide rights to develop, manufacture and commercialize the program. Daiichi declined...
07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: OX40 ligand (OX40L; CD134L)

Autoimmune disease INDICATION: Scleroderma Patient sample and mouse studies suggest inhibiting OX40L could help treat systemic sclerosis. In patient skin and serum samples, OX40L levels were higher than in samples from healthy volunteers. In a...
07:00 , Sep 9, 2013 |  BioCentury  |  Product Development

Checkpoint complementarity

The acquisition of Amplimmune Inc. adds a new set of immune checkpoint targets to MedImmune LLC 's cancer portfolio, giving it more potential combinations to test in cancer. The AstraZeneca plc unit now has four...
07:00 , Jul 29, 2013 |  BioCentury  |  Emerging Company Profile

Jounce: Regulating the regulators

Jounce Therapeutics Inc. is intent on discovering new immune regulatory targets that it hopes will result in a large portfolio of antibody-based immunotherapies to treat many solid cancers. Cancer immunotherapies typically induce T cells to...
07:00 , Jun 18, 2012 |  BioCentury  |  Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Company News

AgonOx, AstraZeneca deal

AgonOx partnered with AstraZeneca's MedImmune LLC subsidiary to develop agonists using AgonOx's OX40 ligand ( OX40L ; CD134L ) technology to treat cancer. MedImmune will lead further preclinical and clinical studies. Details were not disclosed....